Select Language
CCR8
CCR8 Overview
| English Name | C-C chemokine receptor type 8 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 21 | Target Synonym | Chemokine (C-C) Receptor 8，CC Chemokine Receptor 8，CDw198 Antigen，C-C CKR-8，CC-CKR-8，CCR-8，CMKBRL2，C-C Motif Chemokine Receptor 8，CC chemokine receptor CHEMR1，C-C chemokine receptor type 8，Chemokine (C-C Motif) Receptor 8，C-C Chemokine Receptor Type 8，CC Chemokine Receptor CHEMR1，Chemokine Receptor-Like 1，Chemokine (C-C) Receptor-Like 2，CC-Chemokine Receptor Chemr1，CD_antigen=CDw198，Chemokine receptor-like 1，CKRL1，CKR-L1，CMKBR8，GPRCY6，GPR-CY6，TER1，CDw198，CY6 |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | C-C chemokine receptor type 8 |
| Target Synonym | Chemokine (C-C) Receptor 8，CC Chemokine Receptor 8，CDw198 Antigen，C-C CKR-8，CC-CKR-8，CCR-8，CMKBRL2，C-C Motif Chemokine Receptor 8，CC chemokine receptor CHEMR1，C-C chemokine receptor type 8，Chemokine (C-C Motif) Receptor 8，C-C Chemokine Receptor Type 8，CC Chemokine Receptor CHEMR1，Chemokine Receptor-Like 1，Chemokine (C-C) Receptor-Like 2，CC-Chemokine Receptor Chemr1，CD_antigen=CDw198，Chemokine receptor-like 1，CKRL1，CKR-L1，CMKBR8，GPRCY6，GPR-CY6，TER1，CDw198，CY6 |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 21 |
| Highest Development Stage | Phase 3 Clinical |
CCR8 Product List
- Product Category
Protein (8)Cell (1)Antibody (1)
- Product Status
Launched (10)
- Species
Human (7)Mouse (2)Rhesus macaque (1)
- Tag
His Tag & Flag Tag (1)- (7)Flag Tag & His Tag & Strep Tag (2)
- Conjugate
Unconjugated (7)- (1)Biotin-labeled (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT AI CompatibleCC8-H52D6 |  Human | HEK293 | Human CCR8 Protein, Flag,His Tag&Twin-Strep Tag (Detergent) |  | ||
HOT AI CompatibleCC8-H52D7 | Human | HEK293 | Human CCR8 Protein, Flag,His Tag&Twin-Strep Tag (Nanodisc) | | ||
| Human | HEK293 | Human CCR8 Full Length Protein, Flag,His Tag (Nanodisc-pro) |  | | ||
AI Compatible CC8-H52P5 | Human | HEK293 | Human CCR8 Protein (VLP) | | ||
AI Compatible CC8-H82D3 | Human | HEK293 | Biotinylated Human CCR8 Protein, His,Flag Tag&Avitag™ (Detergent) | | ||
AI Compatible CC8-H82D4 | Human | HEK293 | Biotinylated Human CCR8 Protein, His,Flag&Avitag™ (Nanodisc) | | ||
AI Compatible CHEK-ATP140 | Human | HEK293 | HEK293/Human CCR8 Stable Cell Line |  | ||
AI Compatible CC8-M52P3 |  Mouse | HEK293 | Mouse CCR8 Full Length Protein (VLP) | |||
AI Compatible CC8-MY2406 | Mouse | HEK293 | Monoclonal Anti-Human CCR8 Antibody, Mouse IgG2a (11C4C1) (MALS verified) | | ||
AI Compatible CC8-R52P3 |  Rhesus macaque | HEK293 | Rhesus macaque CCR8 Full Length Protein (VLP) | |
Total: 10
- 1
CCR8 Background
This entry represents CC chemokine receptor 8 (CCR8), which it is expressed predominantly in lymphoid tissues and has also been found in glomerular podocytes and human umbilical vein endothelial cells (HUVECs). CCR8 is associated with Th2 lymphocytes, which are critical for allergy, and has a role in lymphocyte activation, migration, proliferation and differentiation and in allergic diseases. CCR8 binds to CCL1 (also known as I-309) and to CCL16 (also known as liver expressed chemokine). It also exhibits a high affinity for three chemokines of viral origin: vMIP-I, vMIP-II and vMCC-I.
CCR8 Synonyms
CC chemokine receptor 8,CDw198,ChemR1,CKRL1,CKR-L1,CKRL1,CY6,GPRCL1,GPRCY6,GPR-CY6,TER-1
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| CCR8 mAb - 01 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
| CCR8 mAb - 02 | Lead | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
| CCR8 mAb - 03 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
Project Cooperation
| Project Name | Drug Type | Therapeutic Area | Indication | Stage | Rights Area |
|---|---|---|---|---|---|
| CCR8 Humanized Antibody | Bispecific antibody | Oncology/Cancer | Solid Tumor | Preclinical | Global |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Cafelkibart | LM-108 | Phase 3 Clinical | LaNova Medicines Ltd | Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Imzokitug | BMS-986340; ONO-7427 | Phase 2 Clinical | Eeig Bristol-Myers Squibb Manufacturing Company Bristol-Myers Squibb Srl | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| TAK- 188 | TAK- 188 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Solid tumours | Details |
| QLP2117 | QLP2117; QLP-2117 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| DT-7012 | DT-7012 | Phase 2 Clinical | Domain Therapeutics SA | Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Neoplasms; Sezary Syndrome; Solid tumours | Details |
| S-531011 | S-531011 | Phase 2 Clinical | Shionogi Inc | Solid tumours | Details |
| IPG-7236 | IPG-7236 | Phase 2 Clinical | Nanjing Immunophage Biotech Co Ltd | Breast Neoplasms; Dermatitis, Atopic; Solid tumours | Details |
| anti-CCR8 antibody (Bristol-Myers Squibb) | Phase 1 Clinical | Bristol-Myers Squibb Company | Solid tumours | Details | |
| PSB-114 | PSB-114 | Phase 1 Clinical | Qilu Puget Sound Biotherapeutics Corp | Neoplasms | Details |
| BAY-3375968 | BAY-3375968 | Phase 1 Clinical | Bayer AG | Neoplasms; Solid tumours | Details |
| ICP-B05 | ICPB05; CM-369 | Phase 1 Clinical | InnoCare Pharma Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Solid tumours | Details |
| HBM-1022 | HBM-1022 | Phase 1 Clinical | Harbour Biomed | Neoplasms | Details |
| Denikitug | JTX-1811; GS-1811 | Phase 1 Clinical | Jounce Therapeutics Inc | Solid tumours | Details |
| Tagmokitug | CHS-114; SRF-114 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| TQB-6457 | TQB-6457; TQB6457 | Phase 1 Clinical | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co Ltd | Neoplasms | Details |
| KYS-2301 | KYS2301; KYS-2301 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Dermatitis, Atopic | Details |
| AMG-355 | AMG 355; AMG-355 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| HC-006 | HC-006; HC006 | Phase 1 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| BGB-A3055 | BGB-A3055 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
| ABBV-514 | ABBV-514 | Phase 1 Clinical | Abbvie Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Ovarian Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| IPGA-05 | IPGA-05; IPG0521; IPG-0521 | Phase 1 Clinical | Nanjing Immunophage Biotech Co Ltd | Autoimmune Diseases; Immunoglobulin G4-Related Disease; Solid tumours | Details |
- Overview
- Product List
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland